Full text is available at the source.
Abstract
Immunogenicity was investigated following bivalent vaccines in hemodialysis patients.
- Hemodialysis patients are at increased risk for severe illness and mortality from COVID-19.
- Bivalent vaccines include antigens from both the ancestral strain and omicron variants BA.1 or BA.4/BA.5.
- The study focuses on the immune response generated by these vaccines in the specific population of hemodialysis patients.
- Findings may provide insights into the effectiveness of vaccination strategies for vulnerable groups.
Simplified